1. Baron EJ (Editor). Medical Microbiology. 4th edition. Bölüm 2. Virology - Hepatitis Viruses 1994. http://www.ncbi.nlm.nih.gov/books
2.
Çull
u F. Çocukluk Çağında A, B, C, Hepatitleri. Viral Hepatit Kitabı-2002. Editörler: Balık I, Tekeli E. Ankara, VHSD, 2002
3. Wong
VC
, Ip HMH, Reesink HW ve ark. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immunglobulin and hepatitis B vaccine. Lancet 1984; 1: 921-6.
4. Jenison SA, Lemon SM, Baker LN, Newbold JE. Quantitative analysis of hepatitis B virus infection DNA in saliva and semen of chronically infect¬ed homosexuel men. J Infect Dis 1987; 156: 299-307.
5. Lin HH, Hsu HY, Chang MH, Chen PJ, Chen DS. Hepatitis B virus in the colostra of HBe Ag positive carrier mothers. J Ped Gastro Nutr 1993; 17: 207-10.
6. Davison F, Alexandre GJM, Trowbridge R, Fagan EA, Williams R. Detection of hepatitis B virus DNA in spermatozoa, urine, saliva and leucocytes of chronic HBs Ag carriers: a lack of relationship with serum markers of replication. J Hepatol 1987; 4: 37-44.
7. Hsu SC, Chang MH, Ni YS, Hsu HY, Lee CY. Horizontal transmission of hepatitis B in children. J Ped Gastroenterol Nutr 1993; 16: 66-9.
8. Wilson RA. Extrahepatic immunological manifestations of chronic hepa¬titis. Am J Gastroenterol1996; 94: 2-16.
42
Kara İH | Akut viral hepatit B
9.
Kanr
a G, Kara A. Hepatit B aşılan. Katkı Pediatri Dergisi 1998; 19: 205¬18.
10. Hsu HY, Chang MH, Hsieh KH ve ark. Cellular immune response to HBc Ag in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15: 770-6.
11.
Çull
u F, Kutlu T, Demirel N ve ark. L'histoire naturelle de l'hepatite a virus B chez les enfants Turcs. Congres Annuel du Groupe Francophone de l'Hepatologie, Gastroenterologie et Nutrition Pediatrique 20-22 Mars
1997 Pisa.
12. Ruiz-Moreno M, Camps T ve ark. Serological and histological follow up of chronic hepatitis B infection. Arch Dis Child 1989; 64: 1165-9.
13. Vanclaire J, Cornu C, Sokal EM ve ark. Fulminant hepatitis B in an infant born to a hepatitis Be antibody positive DNA negative carrier. Arch Dis
Child 1991; 8: 983-5.
14. Dupuy JM, Kostewicz E, Alagille D ve ark. Hepatitis B in children. J
Pediatr1978; 98: 17-20.
15. Ruiz-Moreno M, Rua MJ, Molina J ve ark. Prospective randomised con¬trolled trial of interferon alpha in children with chronic hepatitis B.
Hepatology1991; 13: 1035-9.
16. Sokal EM, Wirth S, Goyens P , Depreterre A, Cornu C. Pediatric use of interferon alpha 2 b therapy in children with chronic hepatitis B infection.
Gut 1993; 34: 87-90.
17. Utili R, Sagnelli E, Galanti B ve ark. Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2 a interferon: a con¬trolled, randomised study. Am J Gastroenterol 1991; 86: 327-30.
18. Çullu F, Tümay GT, Kutlu T, Erkan T, Özbay G, Badur S. Traitement de l'hepatite chronique a virus B de l'enfant par des doses faibles d'inter-feron alpha: resultats a long terme. Gastroenterol Clin Biol 1995; 19: 53-7.
19. Utili R, Sagnelli E, Gaeta GB ve ark. Treatment of chronic hepatitis B in children with prednisone followed by alfa interferon: A controlled ran¬domised study. J Hepatol1994; 20: 163-7.
20. Lai CL, Lin HJ, Lau JN ve ark. Effect of recombinant alfa 2 interferon with or without prednisone in Chinese HBs Ag carrier children. Quarterly J Med 1991; 78: 155-63.
21. Otto LJ, Olson AD. Cost-benefit analysis of interferon therapy in chil¬dren with chronic active hepatitis B. J Pediatr Gastroenterol Nutr 1997; 24:
25-32.
22. Sokal EM, Kelly D, Mizerski J ve ark. An international double-blind placebo-controlled trial of lamivudine in 286 chidren with chronic hepa¬titis B. EASL Meeting, 2001.
23. Shapira R, MorE, Bar-Nathan N ve ark. Efficacy of lamivudine for the treatment of hepatitis B virus infection after liver transplantation in chil¬dren. Transplantation 2001; 72: 333-6.
24. Sokal EM, Roberts EA, Mieli-Vergani G ve ark. A dose ranging study of pharmacokinetics, safety, and preliminary efficacy of lamivudine in chil¬dren and adolescents with chronic hepatitis B. Antimicrob Agents
Chemother 2000; 44: 590-7.
25. Conjeevaram HS. Therapy for chronic hepatitis B: nucleoside analogues in adult and pediatric patients. Acta Gastroenterol Belg 1998; 61: 224-27.
Horsmans Y. New therapeutic possibilities in the treatment of hepatitis B.
Arch Pediatr 1999; 6: 180-2.
Dikici B, Bosnak M, Kara IH ve ark. Lamivudine and Interferon alpha combination treatment of childhood patients with chronic hepatitis B
infection. Pediatr Infect Dis J2001; 20: 988-92.
Schalm SW, Heathcote J, Cianciara J ve ark. Lamivudine and alpha inter-feron combination treatment of patients with chronic hepatitis B infec¬tion: a randomized trial. Gut 2000; 46: 562-8.
Hallauer J. VHPB: summary of strategies and recommandations. Vaccine
1995; 13: 61-3.
Coberly JS, Townsend T, Repke J, Fields H, Margolis H, Halsey NA. Suboptimal response following intradermal hepatitis B vaccine in infants.
Vaccine 1994; 12: 984-7.
Jilg W, Schmidt M, Deinhardt F. Vaccination against hepatitis B: Comparison of three different vaccination schedules. J Infect Dis 1989;
160: 766-9.
Hadler SC, De Monzon MA, Lugo DR, Perez M. Effect of timing of hep¬atitis B vaccine in Yucpa Indians. Vaccine 1989; 7: 106-10.
Chiron JP, Coursaget P, Yvonnet B ve ark. Simultaneous administration of hepatitis B and diphteria/tetanus/polio vaccines. Lancet 1984; 1: 623-4.
Huang LM, Lee CY, Hsu CY ve ark. Effect of monovalent measles and trivalent measles-mumps-rubella vaccines at various ages and concurrent administration with hepatitis B vaccine. Pediatr Infect Dis J1990; 9: 461¬5.
35. Giammanco G, Li Volti S, Mauro L ve ark. Immune response to simulta¬neous administration of recombinant DNA hepatitis B vaccine and mul¬tiple compulsory vaccines in infancy. Vaccine 1991; 9: 747-50.
Kara IH, Yılmaz ME, Süner A, Kadiroğlu AK, Işıkoğlu B. The Evaluation of immune responses that occur after HBV infection and HBV vaccina¬tion in hemodialysis patients. Vaccine 2004; 22: 3963-7.
Dumann H, Meuer SC, Kohler H. Uremic serum inhibits monocyte dependent, but not interleukin 2 dependent steps of T cell proliferation.
Nephron 1990; 56: 162-5.
38. Walz G, Kunzendorf U, Haller H ve ark. Factors influencing the response to hepatitis B vaccination of hemodialysis patients. Nephron 1989; 51: 474-7.
McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA,
Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in
43 618 persons. Am J Med1992; 92: 254-6.
Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J. Major adverse reactions to yeast derived hepatitis B vaccines. Vaccine 1998; 16: 329-34.
Thank you for copying data from http://www.arastirmax.com
